Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tokay, S.
Right arrow Articles by Akoglu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokay, S.
Right arrow Articles by Akoglu, T.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 192-195
© 2001 British Society for Rheumatology

Anticardiolipin antibodies in Behçet's disease: a reassessment

S. Tokay, H. Direskeneli, S. Yurdakul2 and T. Akoglu1

Departments of Rheumatology and,
1 Haematology–Immunology, Faculty of Medicine, Marmara University and
2 Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

Objective. To assess the frequency and clinical relevance of anticardiolipin antibodies (aCL) in Behçet's disease (BD).

Methods. IgG, IgM and IgA aCL isotypes were investigated by ELISA in 128 patients with BD, 143 healthy controls and 20 systemic lupus erythematosus (SLE) patients.

Results. The IgA binding index (BI) was slightly elevated in BD compared with healthy controls (120±53 vs 107±46, P=0.02), whereas IgG and IgM aCL levels were not significantly different (IgG, BD 2.5±2.4 G phospholipid (GPL), healthy controls 2.8±3.6 GPL, P=0.6; IgM, BD 0.7±0.9 M phospholipid (MPL), healthy controls 0.9±1.3 MPL, P=0.6). The frequency of aCL positivity was 7% in BD (IgG 0.8%, IgM 1.6%, IgA 4.6%), 50% in SLE and 5.6% in healthy controls. IgA BI was elevated in the HLA-B5-negative group compared with HLA-B5-positive patients (P<0.005). In a literature review, the frequency of aCL was found to be 9.5% in studies from Turkey compared with 25.5% in other series (P<0.0001).

Conclusion. These results do not suggest a primary role for aCL in BD. A significantly lower frequency of aCL in Turkish BD patients than in other series indicate that regional determinants, whether environmental or genetic, might also play a role in controlling aCL production in BD.

KEY WORDS: Autoantibodies, Anticardiolipin antibodies, Behçet's disease.

Correspondence to: Haner Direskeneli, Resit Pasa Sok, 36/5, Kiziltoprak 81031, Kadiköy, Istanbul, Turkey


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Angotti, D. P. D'Cruz, I. C. Abbs, and G. R. V. Hughes
Renal microinfarction in Behcet's disease
Rheumatology, November 1, 2003; 42(11): 1416 - 1417.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M Leiba, Y Sidi, H Gur, A Leiba, and M Ehrenfeld
Behcet's disease and thrombophilia
Ann Rheum Dis, December 1, 2001; 60(12): 1081 - 1085.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
H Direskeneli
Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51
Ann Rheum Dis, November 1, 2001; 60(11): 996 - 1002.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.